A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Early phase 1	2025-12-19		NCT07294625

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Nanjing Legend Biotech Co.	13
The First Affiliated Hospital with Nanjing Medical University	319

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Henan Cancer Hospital	Zhengzhou	China	98
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	China	6
The Affiliated Hospital of Xuzhou Medical University	Xuzhou	China	28
The First Affiliated Hospital with Nanjing Medical University	Nanjing	China	14
The Second Affiliated Hospital of Xi'an Jiaotong University	Xi’an	China	13